36,612 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Bought by HighTower Advisors LLC

HighTower Advisors LLC acquired a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 36,612 shares of the company’s stock, valued at approximately $136,000.

Several other hedge funds have also modified their holdings of IBRX. Bank of New York Mellon Corp raised its position in ImmunityBio by 37.9% during the second quarter. Bank of New York Mellon Corp now owns 621,536 shares of the company’s stock worth $3,928,000 after acquiring an additional 170,742 shares during the period. CIBC Asset Management Inc purchased a new position in ImmunityBio in the 2nd quarter valued at about $118,000. Rhumbline Advisers boosted its holdings in ImmunityBio by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 211,677 shares of the company’s stock worth $1,338,000 after buying an additional 24,802 shares during the last quarter. Wealth Effects LLC increased its stake in ImmunityBio by 33.6% during the 2nd quarter. Wealth Effects LLC now owns 87,500 shares of the company’s stock worth $553,000 after buying an additional 22,000 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of ImmunityBio by 16.0% during the second quarter. Victory Capital Management Inc. now owns 19,953 shares of the company’s stock valued at $126,000 after acquiring an additional 2,746 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Price Performance

Shares of ImmunityBio stock opened at $2.63 on Thursday. ImmunityBio, Inc. has a 1-year low of $2.50 and a 1-year high of $10.53. The stock has a market cap of $1.83 billion, a P/E ratio of -2.86 and a beta of 0.86. The stock’s 50 day simple moving average is $4.43 and its 200-day simple moving average is $4.66.

Analysts Set New Price Targets

IBRX has been the topic of a number of research analyst reports. EF Hutton Acquisition Co. I raised ImmunityBio to a “strong-buy” rating in a research note on Wednesday, October 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a report on Friday, December 20th.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.